New research reveals that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Findings released in a major medical journal shows that while overweight individuals frequently drop a large proportion of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People using these treatments need to be cognizant of the potential of fast rebound weight gain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to original weight within about a year and a half.
Comparing Therapies
The analysis, which examined 37 of studies involving thousands of patients, contrasted the effects of the injectable medications with other pills.
Researchers note that people who shed pounds through dieting generally see a slower creep back—around 0.1 kg a month—after stopping.
Explaining the Quick Regain
Nutrition scientists propose the mechanism of the jabs accounts for the heightened weight return.
These medications copy a body's own chemical called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement leads to hunger is uncontrolled, making excessive eating much more probable."
An Ongoing Disease?
The NHS recommend the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals say that, given the significant potential of relapse, the therapy might need to be life-long.
This perspective is supported by pharmaceutical companies, who say that the results "highlight the chronic nature of excess weight," similar to managing conditions like hypertension.
Patient Accounts
Individuals who have stopped the medication explain a sudden resurgence of hunger.
"I experienced a trigger flipping and I was suddenly ravenous," said one woman.
This difficulty is exacerbated if individuals have not adopted permanent dietary or behavioural modifications during therapy.
Growing Interest
Survey data suggest that millions of adults in the UK have used these injections in the past year, with demand remaining high.
- Adoption is greater among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Finally, experts emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and lasting health benefits hinges on combined behavioural management.
